To conclude, available evidence suggests improvements in liver enzymes and hepatic steatosis and fibrosis with GLP‐1 receptor agonists, SGLT‐2 inhibitors and TZD derivates. The gene discussed is SLC5A2; the disease is fatty liver disease.